Empowered Funds LLC Purchases 18,345 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Empowered Funds LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 117.5% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 33,963 shares of the biopharmaceutical company’s stock after acquiring an additional 18,345 shares during the quarter. Empowered Funds LLC’s holdings in Regeneron Pharmaceuticals were worth $21,177,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. SHP Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $26,000. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $29,000. Trust Co. of Vermont acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. 83.31% of the stock is owned by institutional investors.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the transaction, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 1,400 shares of company stock valued at $1,090,030. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $807.71 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $847.00. The company has a market capitalization of $83.16 billion, a P/E ratio of 19.96, a P/E/G ratio of 1.39 and a beta of 0.22. The stock has a 50 day moving average of $713.83 and a two-hundred day moving average of $717.85. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.Regeneron Pharmaceuticals’s revenue was up 16.7% on a year-over-year basis. During the same period in the prior year, the company posted $12.81 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone formation and progressive loss of movement. Approval gives Regeneron a new commercial product and strengthens its rare-disease portfolio. However, the small patient population may limit its immediate contribution to earnings. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: A Sound Shore Management investor letter highlighted Regeneron’s need to adjust its strategy following mixed results in melanoma drug trials. The commentary reflects ongoing investor debate about the company’s pipeline and long-term growth, while other market coverage indicates Wall Street remains reasonably constructive on the broader outlook. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Multiple law firms announced or promoted a securities class action concerning allegations that Regeneron misled investors about the prospects of the Phase 3 Fianlimab-Libtayo trial for advanced melanoma. The trial failure reportedly caused a major selloff and an approximately $11 billion decline in market capitalization. The allegations have not been proven, but the litigation adds reputational, legal, and disclosure risk; the lead-plaintiff deadline is September 14, 2026. Regeneron Investors Have Opportunity to Lead Class Action Lawsuit

Analyst Ratings Changes

Several equities analysts have commented on REGN shares. Citigroup increased their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Canaccord Genuity Group dropped their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. Finally, Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. Fifteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $800.36.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.